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The ErbB receptors are tyrosine kinases that bind a
wide variety of ligands. They are implicated in cell
proliferation, generation of anti-apoptotic signals,
differentiation, and cell migration. The over-expres-
sion of different ErbB receptors and/or the expres-
sion of aberrant mutant forms are responsible for
the development of many human cancers. A simpli-
fied view of the mechanism of action of these re-
ceptors is that they are triggered when located at
the cell surface and/or when present in endosomes.
In this review we will discuss a newly emergent,
and more complex, picture in which ErbB receptors
and their ligands translocate to the cell nucleus
where they assume additional functions. The possi-
ble involvement of calmodulin in the translocation
process will be discussed, as well. The development
of new therapeutic strategies targeting the nuclear
translocation system and/or the nuclear functions
of ErbB receptors could help to control the rapid
growth of certain types of tumor cells.
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Translocación al núcleo de receptores
ErbB
Los receptores ErbB son tirosina quinasas que unen
un extenso número de ligandos y están implicados
en proliferación celular, la generación de señales
antiapoptóticas, diferenciación y migración celular.
La sobreexpresión de diferentes receptores ErbB y/o
la expresión de formas aberrantes mutadas son res-
ponsables del desarrollo de muchos tipos de cánce-
res humanos. Una panorámica simplificada del me-
canismo de acción de estos receptores nos enseña
qué señalizan cuando se encuentran en la superfi-
cie celular y/o en endosomas. En esta revisión, sin
embargo, explicaremos nuevos y más complejos
mecanismos por los que los receptores ErbB y sus
ligandos se translocan al núcleo donde ejercen fun-
ciones adicionales. La posible implicación de la cal-
modulina en el proceso de translocación será tam-
bién discutido. El desarrollo de nuevas estrategias
terapéuticas tomando como dianas el sistema de
translocación y/o las funciones nucleares de los re-
ceptores ErbB, podría ayudar al control del creci-
miento rápido en ciertos tipos de células tumorales.
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gion, inducing their homo- or heterodimerization, and
the activation of its intrinsic tyrosine kinase located in
their intracellular region1-3. ErbB3, however, lacks a
functional tyrosine kinase domain, and ErbB2 does
not have a known direct ligand, although both recep-
tors are able to signal upon interaction between them-
selves or with other ErbB family members. The com-
binatorial interaction of different ErbB receptors with
distinct ligands form an array of signaling complexes
able to evoke diverse physiological responses4. Inte-
restingly, the ErbB3:ErbB2 heterodimer is one of the
most potent signaling complexes5. ErbB receptors ge-
nerate multiple cellular responses such as cell prolife-
ration, survival signals, differentiation, and cell moti-
lity. Over-expression and/or the occurrence of a
variety of mutations in different ErbB receptors are
observed in a significant number of human tumors6,7.
35
INTRODUCTION
The epidermal growth factor receptor (EGFR), also na-
med ErbB1/HER1, belongs to the ErbB receptor family,
which is formed by three additional members including
ErbB2/Neu/HER2, ErbB3/HER3 and ErbB4/HER4.
These receptors are highly glycosylated 185-170 kDa
proteins located at the plasma membrane and have a
single transmembrane segment. They bind an extensi-
ve family of polypeptide ligands at its extracellular re-
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A classical view of the signaling mechanisms elicited
by ErbB receptors depicts the following simplified pic-
ture: plasma membrane-located receptors are activa-
ted upon dimerization induced after binding of an 
extracellular ligand, what is followed by its trans(au-
to)phosphorylation, and the recruitment of signaling
molecules bearing Src homology 2 (SH2) or phosp-
hotyrosine binding (PTB) domains at their autophosp-
horylated tyrosine residues. These events generate the
activation of a panoply of signaling pathways bringing
about the translocation of different signaling proteins
into the nucleus, which are involved in the transcrip-
tional regulation of multiple genes required for specific
cellular responses8,9. Thereafter, the receptors are in-
ternalized at clathrin-coated pits, and located at endo-
somes, what is subsequently followed by their degra-
dation at lysosomes to abrogate signaling, or their
recycling back to the cell surface10. Ingenious methods
have been developed, however, to show that endoso-
me-located receptors are also able to generate signa-
ling events11. Nevertheless, in this review we shall dis-
cuss, a radical different picture on the functionality of
ErbB receptors, as they are able to translocate to the
nucleus to exert additional functional roles, opening a
new paradigm on how these receptors operate in a
much more complex manner in living cells.
LOCALIZATION OF ErbB RECEPTOR LIGANDS
INTO THE NUCLEUS
Various polypeptide growth factors have been identi-
fied within the nucleus of multiple cell types, and in
some intriguing cases associating themselves to the
nucleoli12,13. This has caused an exciting debate about
their functional role at this location13,14. In regard to
ErbB receptor ligands, the epidermal growth factor
(EGF)15-21, amphiregulin (AR)15,22, schwannoma-de-
rived growth factor (SDGF)23, and most recently he-
regulin-ß1 (HRGß1)24, have been found in the nu-
cleus, and/or to bind to DNA. Although the nuclear
localization of HRGß1 was first demonstrated in a 
human breast adenocarcinoma cell line24, neither en-
dogenous or exogenous HRGß1 was found to translo-
cate into the nucleus of nonmalignant human mam-
mary epithelial cells25.
The first observation on the nuclear localization of
EGF took place in cultured cells, and it was favored
by the inhibition of lysosomal degradation using chlo-
roquine15. Thereafter, further nuclear localization of
EGF was observed in different cell types16,18,19, and in
regenerating liver17,20, a rapid proliferating tissue.
Nuclear EGF is tightly bound to chromatin, where it
appears to be coupled to a 250-230 kDa protein16,18. In
regenerating liver, EGF is also associated to a high
molecular mass complex17, and binds to nuclear
EGFR with similar affinity than to receptors located
in the plasma membrane20.
AR itself contains two putative nuclear localization
sequences (NLS) and it has been shown indeed to lo-
calize in the nucleus of normal and tumor cells, with
a preferential nucleolar localization in the latter22,26.
Two proteins of 205 kDa and 120 kDa that putatively
could bind to the NLS of AR, have been identified22.
SDGF also contains a nuclear targeting motif, and
this growth factor has been shown to bind to (A+T)-
rich DNA sequences23. Although the precise functions
of these growth factors in the nucleus has yet to be
determined, it has been shown that HRGß1 not only
is translocated to the nucleus but it appears to up-re-
gulate the expression of c-myc in human adenocarci-
noma cells24. Likewise, SDGF seems to induce the
transcription of early genes involved in cell prolifera-
tion, such as nerve growth factor I-A and c-fos23. An
interesting question pending to be answered is whet-
her the observed transcriptional activity is entirely
due to the nuclear growth factors, or there is a parti-
cipation of their cognate receptors also located in the
nucleus.
TRANSLOCATION OF ErbB RECEPTORS INTO
THE NUCLEUS
It is now apparent that the four members of the ErbB
receptor family are capable to be translocated into the
cell nucleus, as we shall discuss herein after, alt-
hough the information concerning ErbB2 and ErbB3
is far more scarce than that for EGFR and ErbB4.
This seemingly unorthodox view has been received
with a mixture of great excitement and some caution
by the scientific community, because the implied
overhaul of a set of text-book ideas on how these re-
ceptors signal to the nucleus via indirect complex
arrays of well established signaling pathways. In rea-
lity, the new findings describe a more complicated
picture, where ErbB receptors are also able to directly
perform different functions within the nucleus. Thus,
several articles commenting the significance and im-
portance of nuclear ErbB receptors have been re-
cently published in very visible journals14,27-29.
EGFR
A hint about a possible functional role of an ErbB re-
ceptor in the nucleus was first described with purified
EGFR, as it was shown to be able to interact and
nicks supercoilled double-stranded DNA in an ATP-
stimulated manner30. Although the nicking process
was latter demonstrated to be due to an associated
protein and not to EGFR itself31, the binding of this
receptor to DNA represented the first unexpected ob-
servation of a more complex drama to start to be un-
folded years later.
Although the association of EGFR to the nuclear en-
velop has been occasionally noticed32, this receptor
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has been clearly detected inside the nucleus of multi-
ple normal cells, and most conspicually in highly pro-
liferating cells, such as in regenerating liver after par-
tial hepatectomy20,33, hepatocellular proliferating cells
after bile duct ligation34, uterus from pregnant mice35,
10-days old mouse embryos35, normal human mouth
mucosa basal cells35, and cells from thyroid tissue of
Graves' disease patients21. Additionally, nuclear
EGFR has been found in cells from human tumor
samples including: adrenocortical carcinoma36, tran-
sitional cell bladder cancer37, thyroid follicular ade-
noma and carcinoma but not papillary carcinoma21,
oral cancer35, and breast cancer35; premalignant hu-
man papillomavirus lesions of the cervix38; and hu-
man tumor cell lines including: SW948 colorectal
carcinoma cells18, squamous carcinoma HN5 cells39,
epidermoid carcinoma A431 cells35, and breast can-
cer MDA-MB-468 cells35.
The addition of EGF or transforming growth factor-α
(TGF-α) induce a time-dependent translocation of
the plasma membrane-located receptor into the nu-
cleus35,39,40, and the presence of serum in the cell
cultures appears to favor the EGF-dependent translo-
cation process39,40. The full-length EGFR, and not a
proteolytically-processed cytoplasmic domain of the
receptor, is the actual translocated species35,39. More-
over, the nuclear EGFR appears to be highly phosp-
horylated at tyrosine residues35. It has been argued
that the observed EGFR could be located at the peri-
nuclear endoplasmic reticulum (ER) network, and
that the confocal microscopy sections used in its de-
tection could be too thick to have adequate resolu-
tion41. These objections, however, were reasonable
answered with further convincing experiments sho-
wing co-localization between nuclear EGFR, DAPI
staining, and a nuclear marker protein (lamin), 
as well as the absence of co-localization of the 
EGFR with ER protein markers (Bip/GRP78 and cal-
nexin)42.
We have determined in living cells transfected with a
chimera between the human EGFR and the green
fluorescence protein (EGFR-GFP) using fluorescen-
ce confocal microscopy, that when the receptor is in-
ternalized upon EGF addition fluorescent spots are
observable in different nuclear planes after prolon-
ged exposure to the growth factor (fig. 1). It is diffi-
cult, however, to ascertain whether the fluorescent
spots observed in the nuclear region represent intra-
nuclear EGFR-GFP. Nevertheless, to maximize the
accumulation of EGFR-GFP into the nucleus we
used leptomycin B, an inhibitor of the nuclear export
chromosomal region maintenance 1 (CRM1) recep-
tor. Thus, blocking the nuclear export system, we ha-
ve obtained convincing evidence of the nuclear loca-
lization of the chimera receptor, as the fluorescence
was clearly associated to the nucleoli after 1 h expo-
sure to EGF (fig. 2). Although the observed event was
EGF-dependent, and therefore likely to have a phy-
siological meaning, further experiments should be
performed to ascertain that the observed nucleolar
fluorescence corresponds to the EGFR-GFP chimera,
and not to processed free GFP. This observation sug-
gests that EGFR is able to locate at the nucleoli, whe-
re it may play important functional roles on mRNA
and/or rRNA processing. This new finding is in agre-
ement with similar observations on the localization
of ErbB3 at the nucleoli25.
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Fig. 1. EGF-dependent internalization of EGFR-GFP in li-
ving cells. Porcine aortic endothelial cells stable transfec-
ted with a human EGFR-GFP chimera (PAE/EGFR-GFP
cells), prepared by Dr. Alexander Sorkin (University of Co-
lorado, Denver CO, USA), were maintained overnight in the
absence of serum, and observed in a Leica SP2 confocal
microscope before and after stimulation with 10 nM EGF
for the indicated times. A 63x HCX Plapo objective with zo-
om was employed, recording the images in the x,y,z-mode
using the 488 nm argon laser, the rsp 500 filter, an Airi 1
pinhole with automatic setting, and focusing the planes at
1 µm intervals from the bottom (z0) to the top (z4) to obtain
the stacks. Three or five planes were recorded, respecti-
vely, before and after EGF stimulation. Notice the massive
accumulation of fluorescence in endosomes because the
EGF-induced internalization of the receptor, and the pre-
sence of conspicuous fluorescent spots in the nuclear re-
gion after EGF stimulation. 
03-translocation  22/10/03  12:38  Página 383
VILLALOBO A, GARCÍA-ANDRÉS C AND MOLINA-ORTIZ P. TRANSLOCATION OF ErbB RECEPTORS INTO THE NUCLEUS
ErbB2
ErbB2 has been shown to translocate to the nucleus
as detected in preparations of isolated nuclei by Wes-
tern blot analysis and immunofluorescence, and the
nuclear translocated receptor was shown to be
phosphorylated at tyrosine residues in greater extent
than its non-nuclear counterpart43.
ErbB3
The full-length ErbB3 has also been shown to trans-
locate into the nucleus of both tumor and nonmalig-
nant mammary epithelial cells, and the presence of
leptomycin B enhances its nuclear localization25. Mo-
reover, ErbB3 was found to be associated to the nu-
cleoli of cells induced to attain epithelial polarity
upon selective growth on permeable filters rather
than in a solid substrate25. Blocking the production of
endogenous HRGß1 with a neutralizing antibody faci-
litates the association of ErbB3 to the nucleoli, and
conversely, the addition of exogenous HRGß1 induces
the translocation of the receptor from the nucleoli to
the nucleoplasm, and thereafter to the cytoplasm25.
From two potential NLSs, the motif RRRR, located in
the C-terminal region of the mature ErbB3 (residues
1183-1186), was identified as the functional NLS of
the receptor by three different methods: a) directing
to the nucleus a chimera of the enhanced green fluo-
rescence protein (EGFP) with the C-terminal seg-
ment of ErbB3 containing the NLS; b) abrogating its
nuclear transport after site-directed mutagenesis of
the NLS; and c) transferring a sequence containing
the NLS to chicken pyruvate kinase, a cytoplasmic
protein, and observing its nuclear localization25.
ErbB4
Occasional immunostaining of nuclei using anti-ErbB4
antibodies was first noticed in some kidney prepara-
tions44. Thereafter, a systematic study on 178 human
invasive breast tumors demonstrated than 
49 % of those gave positive nuclear immunostaining
using two antibodies against the cytosolic region of
ErbB4, whereas only < 5 % of the morphological nor-
384 Rev Oncol 2003;5(7):381-9 38
Fig. 2. EGF-dependent association of EGFR-GFP to the nucleoli. Serum-starved PAE/EGFR-GFP cells were maintained 4 h in
the presence of 37 nM leptomycin B (LmB). Thereafter, 10 nM EGF was added (where indicated) and incubated for the indica-
ted times, fixed with 4 % paraformaldehyde, and observed by confocal microscopy as in figure 1, except that no zoom, and
only the x,y-mode was used. The arrows point to disperse fluorescent spots at the nucleus (30 min frame), and fluorescence
associated to the nucleoli (1 h frame). 
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mal breast epithelium adjacent to the tumor gave a po-
sitive nuclear signal45. This method could therefore be
used to better delineate the area of malignancy within
a biopsy sample. Afterwards, it was shown that ErbB4
is proteolitically processed upon HRG stimulation or
protein kinase C activation with phorbol esters. The
sequential proteolysis is carried out first by the meta-
lloprotease TACE, releasing most of its ectodomain,
and thereafter by γ-secretase, producing an intramem-
brane cleavage that releases the cytosolic region of the
receptor that is translocated to the nucleus as demons-
trated using two ErbB4cyt-GFP constructs46,47.
The γ-secretase is a high molecular mass complex
formed by the endoproteolyzed form of presenilin,
responsible for its catalytic activity, plus nicastrin,
APH-1 and PEN-2, three additional essential cofactor
proteins48. Thus, presenilin inhibitors, or the expres-
sion of a dominant negative presenilin mutant, pre-
vent ErbB4 processing and the nuclear localization of
its cytoplasmic domain46,47. Moreover, the use of lep-
tomycin B favors the nuclear localization of the cyto-
plasmic domain of ErbB4, suggesting that this recep-
tor segment shuttles between the nucleus and the
cytoplasm46.
THE NUCLEAR TRANSLOCATION MECHANISM
An unresolved problem is to determine how a full-
length receptor, as it has been proposed to occur with
the EGFR35,39 and ErbB325, containing its highly hy-
drophobic transmembrane segment, is able to under-
go nuclear translocation through the nuclear pore via
the Ran/importin system. To explain the nuclear
translocation several putative mechanisms have been
suggested.
In the first one, spliced variants lacking the trans-
membrane domain, rather than the native molecule,
could be the actual translocated species, although not
naturally occurring EGFR variants with these charac-
teristics has yet been found14. Nevertheless, a specific
Val to Glu point mutation in the transmembrane do-
main of ErbB2, that changes its high hydrophobic cha-
racter, has been found in a set of tumor cell lines con-
taining activated ErbB249. Moreover, a recombinant
EGFR lacking its transmembrane domain has been
shown to translocate to the nucleus in transfected
cells, but only when the wild type EGFR was co-trans-
fected50. The second plausible proposed mechanism
suggests that the hydrophobicity of the transmembra-
ne domain of the receptor could be masked by its inte-
raction with a chaperone-like protein or other acces-
sory protein(s)14,39. Finally, a direct fusion of the
endosomal and nuclear membranes could occur39.
Although these interesting speculations are worth to
be explored further, hard experimental evidence is ne-
eded to assert the actual molecular mechanism featu-
ring this puzzling translocation process.
In the case of ErbB4, however, the translocation of its
cytosolic domain after the sequential proteolytic pro-
cessing of the plasma membrane bound receptor is
more easy to envisage, as its transmembrane segment
is absent in the translocated species46. At present, it is
not known whether the full-length ErbB2, or only its
cytosolic region, is the actual species translocated to
the nucleus.
POTENTIAL ROLE OF CALMODULIN
REGULATING THE TRANSLOCATION OF ErbB
RECEPTORS INTO THE NUCLEUS
Calmodulin has been implicated in the nuclear im-
port machinery. So, it has been described the existen-
ce of a calmodulin-stimulated GTP-independent nu-
clear import system51. This transport pathway
appears to be operative when the cytosolic concentra-
tion of free Ca2+ increases in stimulated cells, condi-
tions in which the classical GTP-dependent transport
system becomes inhibited51.
A putative NLS in the EGFR has been proposed to
exist in the cytosolic juxtamembrane region of the re-
ceptor (residues 645-657)35,39, and identified as such
by fusing this polypeptidic segment with ß-galactosi-
dase and observing its direct entry into the nucleus35.
Interestingly, we have previously determined that the
overlapping sequence (residues 645-660) constitutes
the calmodulin-binding domain (CaM-BD) of the
EGFR52,53, observation that has been confirmed by ot-
hers54 (fig. 3). Calmodulin directly interacts with the
EGFR modulating its tyrosine kinase activity52,55, and
calmodulin also intervenes in the sorting and recy-
cling of internalized receptors56. We have proposed,
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Fig. 3. The calmodulin-binding domain of the EGFR coinci-
des with its nuclear localization sequence. The cartoon re-
presents the general structure of the EGFR in which the
overlapping sequences corresponding to the calmodulin-
binding domain (CaM-BD)52-54, and the nuclear localization
sequence (NLS)35,39, located in the cytosolic juxtamembra-
ne region (cJM) immediately following the transmembrane
domain (TM), are indicated using the single-letter amino
acid code. 
CaM-BD
RRRHIVRKRTLRRLLQ (645-660)
RRRHIVRKRTLRR (645-657)
NLS
N CExtracelular IntracelularTM cJM
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therefore, that calmodulin could have an additional
role regulating the nuclear translocation of the EGFR,
perhaps occluding its NLS when this process is requi-
red to be prevented57. In this context, it is worth to
mention that nuclear translocation of the transcrip-
tion factor c-Rel is prevented by its interaction with
calmodulin58.
In the case of ErbB4, the motif KKKR (residues 656-
659 of the mature receptor), also located in the cyto-
solic juxtamembrane region, has been suggested to
constitute, among other possible motifs (PFVSRRK
and PEKAKKA), a putative NLS45. This motif is wit-
hin the proposed CaM-BD of ErbB4 (residues 651-
666), as this domain has high homology with the
CaM-BD of the EGFR53,57. This suggests that calmo-
dulin could likewise be involved in the regulation of
the translocation of the cytosolic segment of ErbB4
into the nucleus.
In contrast, and as discussed above, the NLS of ErbB3
(RRRR motif) is not located in its cytosolic juxta-
membrane region but in its C-terminus25. The calmo-
dulin-binding capacity of ErbB3 has not yet been de-
termined. However, although it cannot be excluded
that ErbB3 binds calmodulin, the ortholog region of
ErbB3 corresponding to the CaM-BD of EGFR has
less homology than similar region in other ErbB fa-
mily members53,57. This suggests that if the putative
CaM-BD of ErbB3 were inactive or greatly impaired,
a different NLS could have been selected in the cour-
se of evolution.
FUNCTIONAL ROLE OF ErbB RECEPTORS IN
THE NUCLEUS
As discussed earlier27,28, the most obvious advantage
of the translocation of ErbB receptors into the nu-
cleus is that they can deliver specific signals avoiding
the promiscuity of common signaling pathways sha-
red by other plasma membrane located receptors.
Within the nucleus, it has been proposed14 that there
are four possible functional roles to be exerted by
ErbB receptors: a) transcriptional gene regulation; b)
chromatin remodeling; c) phosphorylation of nuclear
proteins; and d) RNAs processing, particularly at the
nucleoli (fig. 4).
The most exciting finding about the nuclear EGFR is
that it may acts as a transcription factor or a trans-
criptional co-activator. Thus, nuclear EGFR binds in
vivo to (A+T)-rich consensus sequences in the pro-
moter region of cyclin D1, a G1 cell-cycle regulator,
and the C-terminal tail of the receptor containing a
PRR motif is responsible for its transcriptional acti-
vity35. As the whole cytosolic region of the EGFR has
a poor transcriptional activity as compared with its C-
terminal end, it is possible that a negative regulatory
site present in its tyrosine kinase domain could be
responsible for the observed difference in transcrip-
tional power between different EGFR segments35. Al-
ternatively, further intranuclear proteolytic proces-
sing of the EGFR could release the C-terminal seg-
ment with the highest transcriptional activity14.
Nevertheless, as signal transducer and activator of
transcription (STAT) proteins bind to EGFR, it cannot
be excluded that nuclear co-translocation of an
EGFR/STAT complex, or other EGFR/protein com-
plexes, could be responsible for additional transcrip-
tional events.
The potential transcriptional role of nuclear ErbB2
has also been documented43. Hence, the cytoplasmic
domain of ErbB2 fused to the DNA-binding domain of
GAL4 acts as a transcriptional activator in yeast and
mammalian cells, and the C-terminal domain of the
receptor (residues 1075-1260) was shown to be res-
ponsible of its transcriptional activity43. It has been
also suggested that the ErbB4 cytoplasmic domain, or
a segment of its C-terminal region released upon furt-
her intranuclear proteolytic processing, may also in-
tervene in gene transcription28,46.
A sustained increase in tyrosine phosphorylation of
nuclear proteins upon EGF treatment, presumably
carried out at least in part by nuclear EGFR, has been
demonstrated in different cell lines, particularly at the
nucleoli39,40, where their possible involvement in
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Fig. 4. Putative functional roles of ErbB receptors in the nu-
cleus. A plasma membrane-located ErbB receptor
(pmErbB) or its cytosolic domain, released upon sequen-
tial proteolysis by the TACE/γ-secretase system (see text),
are internalized and translocated to the nucleus by an unk-
nown mechanism. As previously discussed14, the propo-
sed functional roles of ErbB receptors located in the nu-
cleus (nErbB) are depicted in a simplified manner: 1,
Full-length and/or fragments of nErbB receptors could act
as transcription factors or transcriptional co-activators. 2,
nErbB receptors could arbitrate chromatin remodeling. 3,
Activated nErbB receptors, perhaps with the concurrence
of their ligands, could phosphorylate nuclear proteins. 4,
nErbB receptors associated to the nucleoli could regulate
transcription of rRNA genes, and/or modulate mRNAs
and/or rRNAs processing. 
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RNA processing has been suspected39. This agrees
with our observation on the association of EGFR-GFP
to the nucleoli (fig. 2). In addition, it has been sugges-
ted that phosphorylation events could regulate the
transcriptional activity of nuclear ErbB428.
Interesting, the EGFR is able to phosphorylate calmo-
dulin in the presence but not in the absence of a basic
protein cofactor, such as histones52,59,60. Although the
use of histones in our earlier in vitro phosphorylation
experiments was not considered to have a physiologi-
cal meaning, the observed translocation of EGFR into
the nucleus has persuaded us to reconsider the possi-
bility that calmodulin could be phosphorylated in in-
tact cells by the nuclear receptor with the concurren-
ce of histones61.
Nuclear EGFR dephosphorylation could be carried
out by a few protein-tyrosine phosphatases located in
the nucleus, including the TC45 form of the T-cell
protein tyrosine phosphatase (TCPTP)62. TC45 exits
the nucleus upon addition of EGF, and dephosphory-
lates several cytosolic phosphoproteins and the mem-
brane bound EGFR, resulting in its inactivation63. Ne-
vertheless, this does not exclude that, additionally,
nuclear TC45 could be involved in the dephosphory-
lation of the EGFR located in the nucleus.
Because the surface-restricted EGFR is fully mitoge-
nic, it has been suggested that the nuclear receptor
could have an antimitogenic rather than a mitogenic
function14,50. Likewise, this has also been suggested
for the nuclear translocated cytosolic domain of
ErbB428,29. Moreover, it has been proposed that diffe-
rent ligands could potentially direct distinct functions
of the nuclear EGFR14.
The translocation of ErbB receptors into the nucleus
appears to be a reversible process, exiting to the cyto-
plasm after their intranuclear functional roles are ac-
complished. In this context, it is interesting to men-
tion that three putative nuclear export signal (NES)
consensus sequences have been identified in the cyto-
solic domain of ErbB446. No information is yet availa-
ble, however, on the occurrence of NES sequences in
other ErbB receptors, although ErbB3 has been
shown to move from the nucleoplasm to the cyto-
plasm in a HRGß1-dependent manner25.
TARGETING NUCLEAR ErbB RECEPTORS:
THERAPEUTIC IMPLICATIONS
Human tumor cells overexpressing ErbB receptors
have been targeted with specific anti-ErbB antibodies
and chemical tyrosine kinase inhibitors to block their
malignant growth64-67. The realization that ErbB re-
ceptors and their ligands are able to be translocated
to the nucleus open the possibility to develop new
drugs that could be used to specifically inhibit the nu-
clear functions of these receptors27. Theoretically, it
could be possible to intervene at several points of the
nuclear cycle of ErbB receptors and/or their ligands,
such as inhibiting their entry into or exit from the nu-
cleus, or their intranuclear functions. In this context,
a recent report shows that the nuclear translocation
of [111In]EGF induces radiotoxicity on human breast
cancer cells overexpressing EGFR, significantly inhi-
biting its growth rate68. It is expected that an impor-
tant research effort would be performed in this regard
in the near future. Nevertheless, more detailed infor-
mation about the submerge molecular mechanisms
responsible for the nuclear translocation process as
well as the actual functional roles of ErbB receptors
and their ligands at the nucleus, must be available to
credit the significance of these findings. If this is
eventually accomplished, the successful development
of therapeutic strategies of clinical relevance could be
achieved.
NOTE ADDED IN PROOF
Recently, another review describing the nuclear loca-
lization and functions of tyrosine kinase receptors,
with special emphasis on ErbB4, has appeared69.
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